VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | The management of high-risk ALL

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, talks on the management of high-risk acute lymphoblastic leukemia (ALL), commenting on the use of bispecific T-cell engagers (BiTE) like blinatumomab and antibody-drug conjugates (ADCs) like inotuzumab ozogamicin, and discussing the role of allogeneic transplantation and CAR-T therapy in this setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter